In memory of
James Van Der Beek

A statement from Guardant Health and Shield™

We are heartbroken by the passing of James Van Der Beek. James was the first brand ambassador for Guardant Health and the Shield™ blood test for colorectal cancer screening, reflecting our shared belief in the power of patient voices.

It was an honor to witness the unwavering commitment he demonstrated over the past year to raising awareness of colorectal cancer and encouraging more people to get screened. His voice and advocacy will leave a lasting mark on the fight against colorectal cancer.

—Guardant Health / The Shield Team

Performance by cancer type:
Shield MCD results report^1,2

The Shield MCD results report is not a part of the FDA approved Shield IVD and has not been cleared or approved by the FDA.

Tumor type	Sensitivity	Primary CSO Accuracy
Bladder	62%	75%
Breast	45%	97%
CRC	83%	88%
Esophageal/Gastric (Stomach)	96%	78%
Liver (Hepatocellular)	94%	60%
Lung	67%	95%
Ovarian	70%	100%
Pancreatic	67%	77%
Prostate	21%	92%

CRC = colorectal cancer; CSO = cancer signal origin; MCD = multi-cancer detection.

In memory of James Van Der Beek

A statement from Guardant Health and Shield™

Additional data2

13%

23%

99.9%

Performance by cancer type: Shield MCD results report1,2

In memory of
James Van Der Beek

Additional data²

13^%

23^%

99.9^%

Performance by cancer type:
Shield MCD results report^1,2